Eli Lilly & Co. vs Neurocrine Biosciences Inc
LLY vs NBIX — side-by-side comparison from reported financials. LLY leads 8, NBIX leads 3 of 11 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Neurocrine Biosciences Inc
NBIX · Healthcare
$142.44+0.84%Strong
| Metric | LLY | NBIX |
|---|---|---|
| Price | $1 177.20 | $142.44 |
| Market cap | $1.05T | $14.5B |
| Revenue (TTM) | $79.7B | $3.37B |
| Revenue growth | +31.7% | +24.3% |
| Net margin | 33.5% | 20.9% |
| Free cash flow | $18.2B | $866M |
| Net cash (debt) | ($35.2B) | $1.01B |
| 1-year price return | +37.6% | +2.9% |
| P/E | 41.6 | 20.5 |
| P/E vs own history (cheap-side %) | 88% | 90% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | 21% |
| Altman Z-score | 7.10 | 6.23 |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 50,000 | 2,500 |
Full résumé-style profiles: LLY CV · NBIX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.